Vepdegestrant + PF-07220060 for Breast Cancer

This trial explores whether two oral medications, vepdegestrant and PF-07220060 (also known as atirmociclib), are safe and effective for treating advanced metastatic breast cancer, a challenging cancer that has spread beyond the breast. The trial seeks participants whose cancer is estrogen receptor positive (sensitive to hormone therapy) and who have stopped responding to previous treatments. Participants will take both medications at home and visit the study clinic approximately every four weeks. The trial continues until the cancer no longer responds or side effects become too severe.

As a Phase 1, Phase 2 trial, this research aims to understand how the treatment works in people and measure its effectiveness in an initial, smaller group, offering participants a chance to contribute to groundbreaking cancer research.

The trial requires that you do not take certain medications, foods, or supplements that strongly affect specific liver enzymes (CYP3A or UGT2B7) or that can cause heart rhythm issues. It's best to discuss your current medications with the trial team to see if any need to be stopped.

Research has shown that vepdegestrant, when used alone, is generally well tolerated by patients with certain types of breast cancer, with most experiencing only mild side effects. It has also proven effective in patients whose breast cancer is difficult to treat.

Regarding PF-07220060, limited information exists about its safety when combined with vepdegestrant. As this trial is in its early stages, researchers are determining the best dose and monitoring for side effects. The treatment has not yet been proven safe in large groups. Notably, both medications are taken orally, which can be more comfortable than injections.

Researchers are excited about Vepdegestrant combined with PF-07220060 because this duo represents a novel approach to treating breast cancer. Unlike standard treatments like hormone therapies or chemotherapy, this combination targets cancer cells in a unique way. Vepdegestrant is an oral selective estrogen receptor degrader, which helps break down estrogen receptors that fuel certain breast cancers. Meanwhile, PF-07220060 is designed to inhibit specific proteins that promote cancer cell growth. Together, these treatments offer a promising new strategy for attacking breast cancer on multiple fronts.

Research shows that vepdegestrant breaks down proteins that help breast cancer cells grow, making it especially promising for tumors that require estrogen. Early studies have shown that PF-07220060 can combat tumors in individuals with advanced solid tumors. In this trial, participants will receive a combination of vepdegestrant and PF-07220060, which might effectively treat advanced metastatic breast cancer, particularly in hormone-sensitive cases that no longer respond to current treatments. Although more research is needed, these early findings offer hope for this challenging condition.¹²³⁵⁶